

1 **Interpretive Summary:** Cost of different types of clinical mastitis in dairy cows. Cha.
2 This study estimated the cost of 3 different types of clinical mastitis (gram-positive,
3 gram-negative and other) in dairy cows, by modification of an existing economic model.
4 We also determined the optimal management decision of whether to keep a cow, replace
5 her with a heifer, or inseminate her, depending on her unique characteristics. This model
6 allows for parameters such as production costs, economic values and disease frequencies
7 to be altered, hence can provide farmers economically optimal guidelines specific to their
8 individual cows.

9
10
11 **COST AND MANAGEMENT OF MASTITIS TYPES IN COWS**

12
13 **Title: The cost and management of different types of clinical mastitis in dairy cows**
14 **calculated by dynamic programming**

15
16
17 **E. Cha,^{*1} D. Bar,⁺ J. A. Hertl,^{*} L.W. Tauer,[‡] G. Bennett,[§] R.N. González,[§] Y.H.**
18 **Schukken,[§] F.L. Welcome,[§] and Y. T. Gröhn^{*}**

19
20 ^{*} Section of Epidemiology, Department of Population Medicine and Diagnostic Sciences,
21 College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA,

22 ⁺ SCR Engineers Ltd., 6 Haomanut St., Poleg, Industrial Zone, Netanya, Israel, 42504,

23 [‡] Charles H. Dyson School of Applied Economics and Management, College of
24 Agriculture and Life Sciences, and

25 [§] Quality Milk Production Services, Department of Population Medicine and Diagnostic
26 Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853

27 ¹Corresponding author: elvacha@gmail.com

28 Tel.: 607-220-3762; fax: 607-253-3083

29

30

31

32 **ABSTRACT**

33

34 The objective of this study was to calculate the cost of 3 different types of clinical
35 mastitis (CM) (due to gram-positive bacteria, gram-negative bacteria and other
36 organisms) at the individual cow level and thereby identify the economically optimal
37 management decision for each type of mastitis. We made modifications to an existing
38 dynamic optimization and simulation model, studying the effects of various factors
39 (incidence of CM, milk loss, pregnancy rate and treatment cost) on the cost of different
40 types of CM. The average costs per case (USD) of gram-positive, gram-negative and
41 other CM were 133.73, 211.03 and 95.31, respectively. This model provided a more
42 informed decision making process in CM management for optimal economic profitability
43 and determined that 93.1% of gram-positive CM cases, 93.1% of gram-negative CM
44 cases and 94.6% of other CM cases should be treated. The main contributor to the total
45 cost per case of gram-positive CM was treatment cost (51.5% of the total cost per case),
46 milk loss for gram-negative CM (72.4%) and treatment cost for other CM (49.2%). The
47 model affords versatility as it allows for parameters such as production costs, economic
48 values and disease frequencies to be altered. Therefore, cost estimates are the direct
49 outcome of the farm specific parameters entered into the model. Thus, this model can
50 provide farmers economically optimal guidelines specific to their individual cows
51 suffering from different types of CM.

52

53 **Key Words.** mastitis, gram-positive, gram-negative, dynamic programming

54

55

56

57

INTRODUCTION

58

59

60 Mastitis reduces dairy farm profitability with losses stemming from both milk
61 production decreases and discarded milk, and treatment and culling costs (Gröhn et al.,
62 2005). The specific inflammatory response from a mastitis incident is dependent on the
63 bacterial species involved (Bannerman, 2008). Depending on the pathogen involved, the
64 impact may vary, so studies determining which pathogens have the greatest impact on
65 cow health, production and profitability are valuable (Gröhn et al., 2004).

66 Treatment for mastitis is the most common cause of antibacterial use on dairy
67 farms. There are public concerns, however, of the possible health hazards posed by the
68 presence of antibiotic residues and other drugs in milk (Erksine et al., 2003). This is
69 despite all bulk tanks being tested for antibiotics. Antibiotic use also raises questions of
70 reduced animal welfare and biosecurity (Sørensen et al., 2010).

71 A fundamental component of mastitis control programs is the identification of
72 pathogens in mastitis samples. For example, the ability to determine whether a cow is
73 suffering from gram-positive or gram-negative CM would help determine the choice of
74 antimicrobial therapy (Waage et al., 1994) and potentially reduce unnecessary use of
75 antibiotics.

76 Most pathogens which cause mastitis can be classified as gram-positive or gram-
77 negative bacteria and determined by on-farm culturing, which is generally faster and
78 more convenient than sending the milk sample to a commercial laboratory (Hertl et al.,
79 2010). The on-farm culture has an approximate 24 h turn-around time. The development
80 of cow-side tests identifying whether a case of mastitis is gram-positive or gram-negative

81 is ongoing (Waage et al., 1994; Yazdankhah, 2001). The objective of this study was to
82 calculate the cost of different types of clinical mastitis (CM) (due to gram-positive
83 bacteria, gram-negative bacteria and other organisms) and to determine the optimal
84 management decision of whether it may or may not be economically optimal for a cow to
85 be (1) replaced with a heifer, (2) kept in the herd (and treated if she has a CM case), but
86 not inseminated or (3) kept (and treated if she has a CM case) and inseminated, for each
87 type of CM. We did this by modifying an existing dynamic programming model
88 previously used to study CM and other diseases in dairy cows (Bar et al., 2008a; Cha et
89 al., 2010).

90

91

MATERIALS AND METHODS

92

Clinical mastitis categorization

94

95 We classified CM into 3 categories: (1) CM due to gram-positive bacteria, (2) CM
96 due to gram-negative bacteria and (3) CM due to other organisms (hereafter, referred to
97 as gram-positive CM, gram-negative CM and other CM).

98 Gram-positive CM included *Streptococcus* spp., *Staphylococcus aureus* and
99 *Staphylococcus* spp. Gram-negative CM included *Escherichia coli*, *Klebsiella* spp.,
100 *Citrobacter* spp. and *Enterobacter* spp. Other CM included *Arcanobacterium pyogenes*,
101 *Mycoplasma* spp., *Corynebacterium bovis*, *Pseudomonas* spp. and yeast.

102

Replacements and inseminations optimization and simulation model

104

105 **Software.** The model was built using the Multi Level Hierarchic Markov Process
106 (MLHMP) software as the application program interface (Kristensen, 2003). We
107 modified an existing optimization and simulation model which was first developed to
108 study the cost of generic CM in dairy cows, then 3 different types of lameness in dairy
109 cows (Bar et al., 2008a; Cha et al., 2010).

110 **The model.** The model was constructed as a 3-level hierarchic Markov process
111 comprised of: the founder (parent) level containing state variables of permanent traits
112 throughout the cow's life span, the child level divided into stages representing one whole
113 lactation, and the grandchild level divided into stages of one month during lactation. The
114 possible actions in a given month of lactation that could occur at the final level are: (1)
115 replace the cow with a calving heifer, (2) keep the cow for another month without
116 insemination and treat her if she has CM or (3) keep the cow for another month and
117 inseminate her and treat her if she has CM (Bar et al., 2008a). Figure 1 is a schematic
118 representation of the model used in the current study on CM. At the founder level, 5 milk
119 yield categories (kg) were modeled as: -5, -2.5, 0, +2.5, and +5 from the mean level of
120 milk production per day; these represented the cow's genetic potential. At the child level,
121 8 possible whole lactation stages were modeled. At the grandchild level, 20 lactation
122 stages (mo) were modeled. In each stage the cow was described by one level within each
123 of the following states: 5 temporary (i.e., daily) milk yield levels, 9 pregnancy states (0 =
124 open, 1-7 = 1-7 mo pregnant and milking and 8 = last 2 mo of pregnancy and dry (not
125 milking)), 1 involuntarily culled state and 13 CM states. The CM states were defined as:
126 0 = no CM, 1 = first occurrence of gram-positive CM (observed at the end of the stage

127 enabling immediate culling with no loss to treatment or production), 2, 3 and 4
128 corresponding to 1, 2, 3 and more mo after the first case of gram-positive CM (this does
129 not mean reoccurrence, but rather time horizon since the first case of gram-positive CM),
130 respectively, 5 = first occurrence of gram-negative CM and 9 = other CM (with numbers
131 from 6-8 and 10-12 corresponding to 1, 2, 3 and more mo after the first case of the CM
132 type, respectively, and again, this does not mean reoccurrence, but rather time horizon
133 since the first case of gram-negative or other CM, respectively).

134 In the case of a reoccurrence, if a cow has reoccurrence of e.g. gram-positive CM,
135 she will return to state 1, when she has a reoccurrence of gram-negative CM, she will
136 return to state 5, and in the case of other CM, she will return to state 9.

137 The objective function maximized by the model was the discounting criterion
138 (Kristensen, 2003), which maximizes the net present value of the cow using a yearly
139 interest rate of 8% (De Vries, 2006; Bar et al., 2008a; Federal Reserve Bank of Kansas
140 City, 2011).

141 ***Optimization technique.*** By combining the advantages of the two types of
142 iteration methods used to solve the Markov Process (namely value iteration and policy
143 iteration), a new notion of a hierarchic Markov process was developed by Kristensen
144 (1988; 1991), which forms the basis of our dynamic program. This solution approach
145 allows us to obtain solutions to large state space problems as described below
146 (Kristensen, 1996).

147 Value iteration is performed to identify the decision that maximizes the total
148 expected discounted rewards when the process starts from state i and continues for n
149 stages before ending. Policy iteration involves choosing an arbitrary set of decision rules

150 for each state at each stage and solving a set of simultaneous linear equations describing
151 the expected future rewards of a process starting from state i and running over an infinite
152 number of stages until the same optimal decision is reached (Kristensen, 1996; Cha et al.,
153 2010). Our model is structured in such a way that a cow can be replaced until time
154 infinity, hence at the founder (parent) level, we have an infinite time horizon. At the
155 subprocess (child and grandchild) levels, however, we have a finite time horizon (i.e., the
156 lifespan of a specific cow).

157 Kristensen (1988; 1991) combined the benefits of both policy and value iteration,
158 by applying value iteration to the subprocesses and using these results in the final step of
159 the policy iteration method of the main process. Hence, in our model, at the founder
160 level, we used policy iteration, and at the child and grandchild levels, value iteration
161 (Figure 1). More details of the mathematics pertaining to this technique can be found in
162 Cha et al., 2010.

163

164 ***Model parameters***

165

166 ***Description of data.*** Model parameters were obtained from analyses of data from
167 7 dairy herds in New York State. These 7 herds were followed for approximately 4 years,
168 and contained a total of 23,902 lactations in 14,208 cows.

169 ***Parameters.*** Model parameters specific to the 3 different types of CM are given in
170 Table 1.

171 A decision to treat a cow with gram-positive CM was associated with a cost
172 (USD) of 73.50. This cost was an estimated average from antibiotics (8), the decreased

173 value of 5d worth of discarded milk from an average production cow (20), 50% of cows
174 receiving anti-inflammatory drugs and fluid IV or per os (15.50), labor (20) and culturing
175 (10). A decision to treat a cow with gram-negative CM was associated with a cost of
176 35.50. This cost was an estimated average from 50% of cows receiving anti-inflammatory
177 drugs and fluid IV or per os (15.50), labor (10) and culturing (10). The decision to treat a
178 cow with other CM was associated with a cost of 49.50. This was an estimated average
179 from antibiotics (4), 50% of cows receiving anti-inflammatory medication and fluid IV or
180 per os (15.50), labor (20) and culturing (10); we assumed the discarded milk could be
181 used in place of milk replacer for calves. Recognizing that the cost of treatment varies by
182 farm (depending on drug administration, days of discarded milk due to drug use, etc.), a
183 sensitivity analysis (described later below) of the cost of treatment was also performed.

184 Pregnancy risk was set to 0.21 per month. Odds ratios which would reduce the
185 rate of conception for each type of CM were applicable only for the first month after the
186 cow got CM (i.e. CM states 1, 5 and 9) and also if she got another case of the same type
187 of CM (where she would return to state 1, 5 or 9 for a recurrent case of gram-positive,
188 gram-negative or other CM, respectively). If a cow contracted CM, her probability of
189 going into the pregnancy state the following month was multiplied by this formula:
190 (pregnancy rate*conception odds ratio for type of CM/(1-pregnancy rate+pregnancy
191 rate*conception odds ratio for type of CM)). The voluntary waiting period was 60 d. The
192 maximum calving interval was 20 mo and the involuntary culling risk at calving was 2%.

193 The monthly risk estimates (first case and recurrent cases), by lactation and CM
194 type, were obtained from generalized linear mixed models with a random herd effect. The
195 monthly risks for repeated cases were an average of the monthly risks for the second and

196 third CM occurrence. The monthly risk estimates for the second CM occurrence in
197 multiparous cows meant the cow could have had any type of CM within the lactation
198 (and no CM in the previous lactation). The monthly risk estimates for the third CM
199 occurrence in multiparous cows referred to cows that had already experienced 2 cases of
200 CM (of any type) within the lactation and without CM in the previous lactation.

201 The cost of a calving first lactation animal (all costs in USD) was 1,600, average
202 monthly cow maintenance cost was 150 and insemination cost/month of insemination
203 was 20. The average price for a calf born was 200. The milk price was \$0.31/kg and the
204 feed cost/kg of dry matter was \$0.20. The cull price for voluntarily culled cows was
205 \$0.74/kg of body weight.

206 Other parameters and prices and costs were taken from Bar, (2007), De Vries
207 (2006) and Bar et al. (2008a). The milk yields, transition probabilities (the probabilities
208 describing the different states a cow can transition to from one month to another), exit
209 from the herd and effects of CM are described in Bar et al. (2008a).

210

211 *Estimating CM cost*

212

213 The average net returns per cow per year for a herd without CM were compared
214 with the average net returns per cow per year for a herd with CM (by type), while
215 keeping other parameters constant. The profit or loss was divided by the CM incidence to
216 generate the herd average cost per case of CM. As the cost of CM was minimized under
217 optimal treatment decisions, it is possible that these values differ from actual farm
218 figures.

219 The effects of milk loss, decreased fertility and treatment cost on the average cost
220 of a CM case were also determined by obtaining the net present values of the model with
221 and without the CM type and effect in question, then dividing by the incidence of CM.

222 The net present value (NPV) is the current value of actions where the benefits and
223 costs of the actions are calculated until the end of the time horizon. This is achieved by
224 discounting the various benefits and costs by an annual interest rate over that time period.
225 An interest rate of 8% was used (De Vries, 2006; Bar et al., 2008a; Federal Reserve Bank
226 of Kansas City, 2011). The discounting factor (β) is equal to $\exp(-r)$ where $r = 0.08$, i.e. β
227 = 0.92. The retention payoff (RPO) value is the NPV of retaining a cow compared with
228 the NPV of her replacement (Bar et al., 2008b), i.e. $NPV_{\text{retaining}} - NPV_{\text{replacing}}$.

229

230 *Exit from the herd*

231

232 Exit from the herd can be due to two reasons: (1) voluntary culling based on what
233 the model recommends or (2) due to what is commonly referred to as involuntary culling.
234 Involuntary culling can be due to euthanasia or cows sold for slaughter because of
235 reasons other than milk yield, pregnancy or CM (i.e. reasons not determined directly from
236 the model). The values used for the probability of involuntary culling are discussed in
237 Bar et al. (2008a). As the probability of involuntary culling of gram-negative mastitic
238 cows was approximately 4 times that of healthy cows, this was reflected in the monthly
239 involuntary culling values used in our model for gram-negative CM (unpublished data).
240 The mortality of gram-negative CM was simplified to be 2% and 4% for primipara and
241 multipara, respectively (Gröhn et al., 2005).

242

243 *Sensitivity analyses*

244

245 Given that economic values such as milk price, replacement cost and treatment
246 cost can vary from time to time and farm to farm, a sensitivity analysis was performed to
247 evaluate how an increase and decrease of 20% in each of these values individually
248 affected the percentage of CM cases in the herd and the average cost per case. Further,
249 we also measured the effect of halving the incidence of all 3 different types of CM, and
250 also the effect of increasing the pregnancy rate by 20% (from 0.21 to 0.25) to determine
251 which of these two management measures have the most beneficial effect on the average
252 cost/case of CM.

253

254

RESULTS

255

256 *The cost of different types of CM*

257

258 The effects of each different type of CM on net return, incidence of CM, percent
259 of CM cases treated, average cost of CM and average cost per case, are shown in Table 2.
260 The monetary values correspond to averaging over cow characteristics (parity, month of
261 lactation, etc.). The average cost per case (USD) was greatest for gram-negative CM at
262 211.03 (32.71/0.155) (where 32.71 is the average cost (=390.06-357.35) and 0.155 is the
263 incidence of gram-negative CM), followed by gram-positive CM at 133.73 (16.85/0.126),
264 and other CM at 95.31 (15.44/0.162). The percentage of mastitic cows recommended to

265 be treated, following an optimal replacement policy, was 93.1, 93.1 and 94.6 for gram-
266 positive, gram-negative and other CM, respectively. For the remainder of cows, the
267 recommended policy was to cull immediately.

268

269 *The effects of exogenous factors on the cost of different types of CM*

270

271 We quantified how penalties associated with each type of CM, i.e., the milk loss,
272 decreased fertility and treatment cost, contribute to the average cost per case of each type
273 of CM. For gram-positive CM, the total cost (133.73) was comprised mostly of the
274 treatment cost (68.89; 51.5% of the total cost), followed by milk loss (49.64; 37.1%) and
275 decreased fertility (15.20; 11.4%). For gram-negative CM, the total cost (211.04) was
276 primarily from the milk loss (152.76; 72.4%), followed by treatment cost (32.74; 15.5%)
277 and decreased fertility (25.54; 12.1%). For other CM, the same trend was seen as for
278 gram-positive CM, i.e. the treatment cost (46.86; 49.2%) contributed most to the total
279 cost (95.30), followed by milk loss (38.64; 40.5%) and decreased fertility (9.80; 10.3%).

280 We increased and decreased the milk price by 20%, to observe how sensitive the
281 average cost/case was to milk prices for each type of CM (Table 3). When we increased
282 the milk price by 20%, the average cost/case of all CM increased by 11.7% (from 155.08
283 to 173.23), and decreased by 11.1% (from 155.08 to 137.91) when we decreased milk
284 price by 20%. Gram-negative CM was most sensitive to these changes; the average cost
285 per case increased by 14% (from 211.03 to 240.63) and decreased 13.1% (from 211.03 to
286 183.37) when milk price was increased and decreased by 20%, respectively.

287 When we increased and decreased the replacement cost by 20%, the average
288 cost/case of CM increased by 5.3% (from 155.08 to 163.23) and decreased by 4.1% (from
289 155.08 to 148.67), respectively (Table 3). Gram-negative CM was most sensitive to these
290 changes; the average cost/case increased by 6.7% (from 211.03 to 225.15) and decreased
291 by 5.2% (from 211.03 to 200.06) when replacement cost was increased and decreased by
292 20%, respectively.

293 When we increased and decreased the treatment cost by 20%, the greatest change
294 in cost/case was seen for gram-positive CM (increase of 10.4%, from 133.73 to 147.60,
295 and decrease of 10.2%, from 133.73 to 120.13, respectively), followed by other CM
296 (increase of 9.2%, from 95.31 to 104.10, and decrease of 8.9% from 95.31 to 86.84), and
297 gram-negative CM (increase of 3.6%, from 211.03 to 218.57, and decrease of 3.4% from
298 211.03 to 203.96) (Table 3).

299 The average cost per case increased when the incidence of all different types of
300 CM was halved. The greatest increase was in the other CM category (from 95.31 to
301 98.47, a 3.3% increase) (Table 3).

302 When pregnancy rate was increased by 20%, the average cost per case decreased.
303 Of the 3 categories of CM, the largest decrease was seen in the other category (from
304 95.31 to 92.70, a 2.7% decrease) (Table 3).

305

306 ***Retention payoff of open healthy and mastitic cows***

307

308 Our economic model calculates the retention payoff for cows, dependent on their
309 individual characteristics. Figures 2 and 3 are hypothetical examples of retention payoffs

310 under an optimal policy for cows free of CM and with different types of CM, specific to
311 an open (non-pregnant), second lactation cow with average milk yield per 305 day
312 lactation, and with permanent milk yield of 1,500 kg per 305 day lactation less than the
313 average in the herd, respectively. The optimal policy recommended by the model (keep
314 but not inseminate, keep and inseminate or replace) is also illustrated by the symbols on
315 the graph.

316 In Figure 2, the RPO (USD) of cows at calving was 1,227, 1,091, 1,053 and 933
317 for no CM, other CM, gram-positive CM and gram-negative CM, respectively. The
318 average cost at calving was calculated by subtracting the RPO for the different types of
319 CM from the RPO for no CM. The average cost at calving was 136 (1,227-1,091), 174
320 (1,227-1,053) and 294 (1,227-933) for other CM, gram-positive CM and gram-negative
321 CM, respectively. When the RPO is negative, it is more profitable to cull the cow than
322 keep her. This was observed at month 12 for no CM, month 11 for other CM, and month
323 10 for gram-positive and gram-negative CM. Our figure illustrates the recommended
324 policy until month 14; cows in month 14 and onwards were all recommended to be
325 replaced.

326 In Figure 3, it can be seen that the culling recommendation has shifted forward,
327 i.e., culling was recommended at month 9 for a cow without CM, and at month 7 for
328 cows with gram-positive, gram-negative and other CM. The RPO of these cows at
329 calving was 626, 518, 481 and 422, for no CM, other CM, gram-positive and gram-
330 negative CM, respectively. Therefore, the average cost at calving was 108 (626-518), 145
331 (626-481) and 204 (626-422) for other CM, gram-positive and gram-negative CM,

332 respectively. Our figure illustrates the recommended policy until month 12; cows in
333 month 12 and onwards were all recommended to be replaced.

334

335 *Endogenous factors affecting the cost of CM*

336

337 Tables 4 and 5 are a cross-sectional view of Figures 2 and 3 at 4 and 8 months
338 after calving, respectively (but with more information than the figures, i.e., Tables 4 and
339 5 also include cows of high permanent milk yield potential and pregnant cows).

340 The cost of CM is dependent on endogenous factors, i.e., permanent (genetic)
341 milk yield potential, pregnancy status and lactation (Tables 4 and 5). The general trends
342 are discussed below.

343 For a cow 4 months after calving (Table 4), we found that the average cost of CM
344 was greater in open cows compared with pregnant cows. Also, the average cost of CM
345 was greater in younger cows compared with older cows.

346 The average cost was greatest for gram-negative CM, followed by gram-positive
347 CM, and other CM, for each permanent milk yield potential and pregnancy status
348 combination. Also, the cost was greatest for cows that were high milk producing,
349 followed by average and low producing.

350 At 8 months after calving (Table 5), the average cost was generally greater for
351 cows suffering from gram-negative CM, and this was followed by gram-positive CM and
352 other CM. Also, in the low permanent milk yield potential category, pregnant cows had a
353 higher average cost of CM compared with open cows, but this was reversed in the
354 average and high permanent milk yield potential categories. Similar to the trend at 4

355 months after calving, younger cows had a higher average cost of CM than older cows and
356 the higher the permanent milk yield potential of the cow, the greater the average cost of
357 CM (Table 5).

358

359 *Exit from the herd (voluntary culling and involuntary culling)*

360

361 When all the different types of CM were included in the model, the percentage
362 exit from the herd was 35.5 (comprised of 17% from voluntary culling and 18.5% from
363 involuntary culling). This increased to 38.7 (20.8, 17.9) when milk price was increased
364 by 20%, and decreased to 33.1 (13.8, 19.3) when milk price was reduced by 20%. When
365 replacement cost was increased by 20%, herd exit decreased to 33.6 (14.4, 19.2) and
366 increased to 39.3 (17.5, 21.8) when replacement cost was reduced by 20%. When the
367 incidences of CM were halved, herd exit decreased to 34.4 (15.7, 18.7), and when
368 pregnancy rate was increased by 20%, it decreased to 33.4 (13.8, 19.6).

369

370

DISCUSSION

371

372 When a cow contracts mastitis, the dairy farmer needs to decide whether
373 treatment is warranted, and if so, what treatment is most appropriate. These decisions are
374 ideally made based on the organism causing mastitis. In determining how to treat a cow,
375 one common way of grouping these organisms is to separate them into gram-positive and
376 gram-negative mastitis. These two groups of organisms cause mastitis of different

377 symptoms and severity. This classification can form the basis of on-farm treatment
378 protocols (Hertl et al., 2010).

379 The importance and reliance on classifications of mastitis has become prevalent in
380 the literature. For example, a study conducted by Neeser et al. (2006) found that there
381 were significant reductions in the amount of antimicrobial use when on-farm culture
382 systems were employed. Most producers treated gram-positive mastitis with antibiotics,
383 whereas gram-negative mastitis treatment varied. They concluded that the reduction in
384 antimicrobial use could lead to several advantages, such as decreases in discarded milk
385 and antimicrobial residues in milk, and improved treatment outcome due to targeted
386 treatment. From our study, we found the average cost per case (USD) of gram-negative
387 CM (211.03) was due mostly to milk loss, which is logical given that the milk loss was
388 greatest for gram-negative CM out of the 3 types of CM (see also Schukken et al.
389 (2009)). For gram-positive CM, this cost was primarily due to the treatment cost, which
390 is also intuitive, given that the treatment cost was greatest for gram-positive CM, of all 3
391 types of CM. Similarly, treatment cost contributed most to the average cost per case of
392 other CM.

393 The average cost per case with all 3 different types of CM in the model was
394 155.08, which is lower than that found in the study by Bar et al. (2008a) for generic CM,
395 where the average cost per case was 179. This difference is due to a number of reasons:
396 our model was more detailed in that generic mastitis was differentiated into types and
397 data in our study were updated from Bar et al. (2008a), In Bar et al. (2008a) the
398 parameter values used in the model (risk, treatment cost, involuntary culling, etc.) were
399 for generic CM and not groups of CM, and we did not include a carryover state from the

400 previous lactation. Unlike the generic CM case, if we were to include a carryover state,
401 we would need to model all the different combinations of carryover effects possible (e.g.
402 gram-positive CM in previous lactation, gram-negative CM in current lactation, or gram-
403 positive CM in previous lactation, gram-positive CM in current lactation, etc.). This
404 would cause the state-space of the model to grow considerably, increasing the time and
405 computer capacity necessary to calculate an optimal solution. The inclusion of carryover
406 effect is an area of future research.

407 Although a few studies have examined the cost of CM in dairy cows, none have
408 quantified this cost at the individual cow level for 3 different types of CM. The study that
409 comes closest to examining such costs was conducted by Sørensen et al. (2010). In that
410 study, the authors estimated the costs related to 5 different pathogen-specific mastitis
411 traits and unspecific mastitis using a stochastic simulation model (SimHerd IV). Costs
412 ranged from 189.42USD to 724.64USD per case (converted on 20Aug2010 from €149
413 and €570, respectively), and were greater for contagious pathogens, compared with
414 environmental pathogens.

415 In our study, not only did we calculate the cost of different types of CM, but also
416 the sensitivity of these costs from parameter changes. When we increased the milk price,
417 the average cost per case of CM increased, as the milk losses associated with each type of
418 CM were higher valued. The reverse was seen when milk price was reduced. Again, as
419 expected, the average cost of gram-negative CM was most sensitive to this change. The
420 same pattern was observed when replacement cost was increased.

421 We increased and decreased treatment cost by 20% to account for differences
422 across farms in e.g. the use of antibiotics and associated discarded milk. What we found

423 was, despite these changes, the order of the cost of CM from most costly to least costly
424 did not change (i.e. gram negative was always most expensive, followed by gram positive
425 then other CM).

426 Between the two scenarios of increasing pregnancy rate or halving the incidence
427 of CM, it was apparent that the former case led to a reduction in the average cost/case of
428 CM, indicating the benefits to farmers of focusing on improving their breeding programs.
429 The reason for the average cost per case of CM increasing when the herd CM incidence is
430 halved is because when the chance of a cow having another CM case in the future is
431 lower, there is a tendency to treat instead of cull, and overall this increases the average
432 cost per case of CM.

433 Both Figures 2 and 3 illustrate that cows with CM should be replaced earlier than
434 cows without CM, and that cows with lower milk yield should be replaced earlier than
435 cows with higher milk yield. From Figure 3, it can be seen that cows with gram-negative
436 CM are recommended to be inseminated only once compared with cows having gram-
437 positive and other CM; this can be attributed to the greater milk loss from gram-negative
438 CM (Schukken et al., 2009), making it less economically optimal to spend the money on
439 inseminating them from that one point onwards. The cross sectional views of the figures
440 (Tables 4 and 5) quantified what one would expect in the average cost/case of CM, as
441 permanent milk yield, age, type of CM and pregnancy status vary. For example, as
442 permanent milk yield potential increased from low to high, the average cost/case of CM
443 increased. As expected, the older the cow is, the lower the average cost/case of CM, as an
444 older cow has less lifespan remaining, than a younger cow, for the cow to succumb to the
445 detrimental effects of disease (and for these to be translated into monetary losses). Gram-

446 negative CM generated the highest cost, as has been the case so far. Generally, CM cases
447 were more costly in open cows, as they have the added effect of reduced fertility (unlike
448 pregnant cows, as they are already with calf). Among cows 8 mo after calving (Table 5),
449 in the low permanent milk yield potential category, however, pregnant cows had a higher
450 average cost of CM compared with open cows, which is due to these cows being further
451 into pregnancy, and a greater probability of going to term (unlike cows at 4 mo, where
452 the opposite trend was seen in average cost/case of CM).

453 As anticipated, when milk price increased, culling (voluntary) increased as well,
454 due to the increased cost from milk loss and the greater expected profit of a replacement
455 heifer. When the incidence of CM was halved, and pregnancy rate increased, culling
456 (voluntary) percentages decreased. When replacement cost increased, culling (voluntary)
457 was reduced, as it was more expensive to replace than to keep a cow.

458 In our model, we use a monthly time step, where we assume that e.g. all CM cases
459 occurring 152 – 183 days after calving occur at day 183, enabling the decision to cull
460 (and not treat) before incurring the costs of disease. The only exception to this is the first
461 stage after calving which has a length of only 3 days, i.e. we assume that all cows that
462 have mastitis shortly after calving have it by the third day after calving (Bar et al.,
463 2008a). This is also because we estimate a greater risk for CM in these days.

464 Our study focuses on decisions for individual animals, and as such is an
465 individual based model. All modeling techniques have their advantages which need to be
466 weighed with their disadvantages in selecting the technique most appropriate for the
467 study. The limitations of our individual cow model are that we cannot include herd
468 dynamics, e.g. infectivity of CM, and see the effects of this at the individual cow level. If

469 the latter were the focus of our study, then another modeling technique would be
470 appropriate.

471 Our research was specific to cow characteristics which allows us to undertake a
472 comprehensive analysis of the costs of CM by type. Further, the cost of disease depends
473 on the fate of the cow. If the cow is to be culled, milk loss effects and fertility effects are
474 not applicable. If the cow is pregnant, disease effects on fertility are not applicable.
475 Pregnant cows were almost always recommended to be kept in the herd until the next
476 lactation. Because the CM losses in these cows are only the treatment cost and milk loss
477 and these were assumed to be the same for both high yielding cows and low yielding
478 cows, the cost of CM is the same for all these pregnant cows. Intuitively, one would
479 assume that a high producing cow loses more milk to CM (compared with an average or
480 low producer); however, we have assumed this to be the same. While we know that high
481 milk production is a risk factor for mastitis (Gröhn et al., 1990; Gröhn et al., 1995), we
482 have not investigated whether these losses are different for low or high milk producing
483 cows, though this would not be unexpected. Because we do not included this risk factor
484 in our model, and assume that milk loss is consistent across all milk production levels, it
485 is possible that there may be more variability in the results than currently shown in our
486 model.

487 Further, we did not model seasonality and milk component variations, or the exact
488 shape of the lactation curves beyond 10 mo, as these issues were beyond the scope of our
489 study objectives. A further limitation includes the assumption that the farmer has
490 complete knowledge of cow traits, and that a replacement heifer immediately enters the

491 milking herd following a cow replacement, which is not always the case (Bar et al.,
492 2008a).

493 The ‘treat’ decision which our economic model can recommend does not take into
494 account how effective the treatment may be. And given that in our current model, CM is
495 divided into 3 categories of gram-positive, gram-negative and other CM, the treatment
496 policies for each type of bacteria in each category are assumed to be the same.
497 Admittedly, the success and type of treatment for bacteria within each group, or even the
498 same bacterial species between different strains, can differ; however, the focus of our
499 economic model was not to assess the success of different types of treatment options.

500 This model, therefore, serves as a decision tool to aid farmers when deciding what
501 to do with their diseased cows. The economic values, production costs and disease
502 frequencies can be altered, hence, the results can be made applicable to individual farms,
503 although our used values are representative.

504

505

ACKNOWLEDGEMENTS

506

507 The USDA (CSREES) Award No. 2010-65119-20478 provided funding for this
508 study. The authors thank the owners and personnel from the 7 dairies and the personnel
509 of the Ithaca, Canton, and Geneseo Regional Laboratories of Quality Milk Production
510 Services for their valuable cooperation.

511

512

513

514 **REFERENCES**

515

516 Bannerman, D. D. 2008. Pathogen-dependent induction of cytokines and other soluble
517 inflammatory mediators during intramammary infection of dairy cows. *J. Anim.*
518 *Sci.* 87(Suppl. 1):10-25.

519 Bar, D. 2007. Cost of generic clinical mastitis in dairy cows. PhD Thesis. Cornell
520 University, Ithaca, NY.

521 Bar, D., L. W. Tauer, G. Bennett, R. N. González, J. A. Hertl, Y. H. Schukken, H. F.
522 Schulte, F. L. Welcome, and Y. T. Gröhn. 2008a. The cost of generic clinical
523 mastitis in dairy cows as estimated using dynamic programming. *J. Dairy Sci.*
524 91:2205-2214.

525 Bar, D., L. W. Tauer, G. Bennett, R. N. González, J. A. Hertl, H. F. Schulte, Y. H.
526 Schukken, F. L. Welcome, and Y. T. Gröhn. 2008b. Use of a dynamic
527 programming model to estimate the value of clinical mastitis treatment and
528 prevention options utilized by dairy producers. *Agric. Syst.*, 99:6-12.

529 Cha, E, J. A. Hertl, D. Bar, and Y. T. Gröhn. 2010. The cost of different types of
530 lameness in dairy cows calculated by dynamic programming. *Prev. Vet. Med.* 97:
531 1-8.

532 De Vries, A. 2006. Economic value of pregnancy in dairy cattle. *J. Dairy Sci.* 89:3876-
533 3885.

534 Erskine, R. J., S. Wagner, and F. J. DeGraves. 2003. Mastitis therapy and pharmacology.
535 *Vet. Clin. Food Anim.* 19:109-138.

536 Federal Reserve Bank of Kansas City. Agricultural Credit Survey ‘Interest Rate Data –
537 Agricultural Interest Rates: Operating Loans, Federal Reserve Bank of Kansas
538 City-Tenth Federal Reserve District, Quarterly Agricultural Credit Survey’
539 <http://www.kansascityfed.org/research/indicatorsdata/agcredit/> (accessed 23 Jan
540 2011).

541 Gröhn Y.T., H.N. Erb, C.E. McCulloch, and H.S. Saloniemi. 1990. Epidemiology of
542 mammary gland disorders in multiparous Finnish Ayrshire Cows. *Prev. Vet. Med.*
543 8:241-252.

544 Gröhn, Y. T., S.W. Eicker, and J.A. Hertl. 1995. The association between previous 305-
545 day milk yield and disease in New York State dairy cows. *J. Dairy Sci.* 78:1693-
546 1702.

547 Gröhn, Y. T., D. J. Wilson, R. N. González, J. A. Hertl, H. Schulte, G. Bennett, and Y. H.
548 Schukken. 2004. Effect of pathogen-specific clinical mastitis on milk yield in
549 dairy cows. *J. Dairy Sci.* 87:3358-3374.

550 Gröhn, Y. T., R. N. González, D. J. Wilson, J. A. Hertl, G. Bennett, H. Schulte, and Y. H.
551 Schukken. 2005. Effect of pathogen-specific clinical mastitis on herd life in two
552 New York State dairy herds. *Prev. Vet. Med.* 71:105-125.

553 Hertl, J. A., Y. T. Gröhn, J. D. G. Leach, D. Bar, G. J. Bennett, R. N. González, B. J.
554 Rauch, F. L. Welcome, L. W. Tauer, and Y. H. Schukken. 2010. Effects of
555 clinical mastitis caused by gram-positive and gram negative bacteria and other
556 organisms on the probability of conception in New York State Holstein dairy
557 cows. *J. Dairy Sci.* 93:1551-1560.

558 Kristensen, A. R. 1988. Hierarchic Markov processes and their applications in
559 replacement models. *Eur. J. Oper. Res.* 35:207-215.

560 Kristensen, A. R. 1991. Maximization of net revenue per unit of physical output in
561 Markov decision processes. *Europ. Rev. Agr. Econ.* 18:231-244.

562 Kristensen, A. R. 1996. Textbook notes of herd management: Dynamic programming and
563 Markov decision processes. Dina Notat No. 49, Dept. of Animal Science and
564 Animal Health, Royal Veterinary and Agricultural University, Denmark.

565 Kristensen, A. R. 2003. A general software system for Markov decision processes in herd
566 management applications. *Comput. Electron. Agric.* 38:199-215.

567 Neeser, N. L., W. D. Hueston, S. M. Godden, and R. F. Bey. 2006. Evaluation of the use
568 of an on-farm system for bacteriologic culture of milk from cows with low-grade
569 mastitis. *JAVMA*, 228:254-260.

570 Schukken, Y. H., J. Hertl, D. Bar, G. J. Bennett, R. N. González, B. J. Rauch, C.
571 Santisteban, H. F. Schulte, L. Tauer, F. L. Welcome, and Y. T. Gröhn. 2009.
572 Effects of repeated gram-positive and gram-negative clinical mastitis episodes on
573 milk yield loss in Holstein dairy cows. *J. Dairy Sci.* 92:3091-3105.

574 Silva, B. O., D. Z. Caraviello, A. C. Rodrigues, and P. L. Ruegg. 2005. Evaluation of
575 petrifilm for the isolation of *Staphylococcus aureus* from milk samples. *J. Dairy*
576 *Sci.* 88:3000-3008.

577 Sørensen, L. P., T. Mark, M. K. Sørensen, and S. Østergaard. 2010. Economic values and
578 expected effect of selection index for pathogen-specific mastitis under Danish
579 conditions. *J. Dairy Sci.* 93:358-369.

580 Waage, S., P. Jonsson, and A. Franklin. 1994. Evaluation of a cow-side test for detection
581 of gram-negative bacteria in milk from cows with mastitis. *Acta vet. scand.*
582 35:207-212.

583 Yazdankhah, S. P., H. Sørum, H. J. S. Larsen, and G. Gogstad. 2001. Rapid method for
584 detection of gram-positive and –negative bacteria in milk from cows with
585 moderate or severe clinical mastitis. *J. Clin. Microbiol.* 39:3228-3233.

586
587
588